Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the Company.
The purchases made on the 21st July 2022 are detailed in the table below:
| Director/PDMR | No. of Ordinary Shares purchased | Purchase price per Ordinary Share | Total no. of Ordinary Shares held | Percentage ownership of total issued share capital |
| Matthew Stork | 22,950 | £1.13 | 147,950 | 0.47% |
| Stephen Symonds | 22,950 | £1.13 | 22,950 | 0.07% |
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
